Survival in Parkinson's disease. Relation with motor and non-motor features
Introduction
Survival in patients with Parkinson's disease (PD) is reduced as compared to the general population, with mortality hazard ratios ranging from 1.5 to 2.7 [1], [2], [3], [4], [5], [6], [7]. Knowledge on factors associated with increased mortality in PD may provide more insight in the pathophysiology and course of the disease and will allow clinicians to inform individual patients more adequately about their prognosis. Several studies have sought to determine which factors predict mortality in PD. Older age, male sex, severity of motor symptoms, dementia, and gait dysfunction were found to be associated with reduced survival in previous studies [1], [2], [6], [7], [8], [9], [10], [11], [12], [13]. However, most of these studies individually investigated only a limited number of variables, and focused mainly on demographic, motor, and cognitive features. Therefore, knowledge of the influence on mortality of non-motor symptoms other than dementia (including depression, daytime sleepiness, psychotic symptoms, and autonomic dysfunction) is scarce.
We aimed to identify predictors of mortality in a prospective study among 414 PD patients who underwent extensive, standardized assessment of a large number of motor and non-motor symptoms.
Section snippets
Study design
The current study was carried out within the ‘PROfiling PARKinson's disease’ (PROPARK) study, a longitudinal hospital-based cohort study of 414 patients with PD with extensive annual evaluation of different clinical domains. All patients fulfilled the United Kingdom Parkinson's Disease Society Brain Bank criteria for idiopathic PD [14]. Patients were recruited from both university and regional hospitals from the western part of The Netherlands. The recruitment procedure of the PROPARK study has
Results
Table 1 displays the baseline characteristics of the study population. The total number of person years of follow-up for the cohort was 1790.51. During a mean follow up per patient of 4.32 (range 0.23–6.28) years, 49 patients (11.8%) died. In the course of the study period 56 patients (13%) were lost to follow-up. Reported causes of death were malignancy (n = 9), cardiac disease (n = 9), infection or sepsis (n = 7), stroke (n = 4), accident (n = 2), pulmonary embolism (n = 1), suicide (n = 1),
Discussion
In this prospective study among a hospital-based cohort of 414 PD patients we found that higher age, male sex, cognitive impairment, higher PIGD score, and psychotic symptoms were independent predictors of decreased survival in PD patients. Depression and disease severity were associated with mortality in the models adjusted for age, sex, and disease duration, but were no longer statistically significant in the multivariable stepwise regression model.
Methodological strengths of this study are
Acknowledgements
This work was supported by a grant from the Dutch Parkinson's Disease Society (JJvH). The funding source had no role in the study design, collection, analysis, and interpretation of data, or writing of the report.
None of the authors has potential conflicts of interest that relate to the manuscript.
References (30)
- et al.
Epidemiologic observations on Parkinson's disease: incidence and mortality in a prospective study of middle-aged men
Neurology
(1996) - et al.
Mortality from Parkinson disease
Arch Neurol
(1997) - et al.
The Sydney multicentre study of Parkinson's disease: progression and mortality at 10 years
J Neurol Neurosurg Psychiatry
(1999) - et al.
Survival study of parkinson disease in Olmsted County, Minnesota
Arch Neurol
(2003) - et al.
Mortality and Parkinson disease: a community based study
Neurology
(2004) - et al.
Prognosis of Parkinson disease: risk of dementia and mortality: the Rotterdam study
Arch Neurol
(2005) - et al.
Mortality from Parkinson's disease: a population-based prospective study (NEDICES)
Mov Disord
(2011) - et al.
Dementia and survival in Parkinson disease: a 12-year population study
Neurology
(2008) - et al.
What predicts mortality in Parkinson disease?: a prospective population-based long-term study
Neurology
(2010) - et al.
The association of incident dementia with mortality in PD
Neurology
(2002)
Clinical features in early Parkinson disease and survival
Arch Neurol
Predictors of survival in patients with Parkinson disease
Arch Neurol
Ten year survival and outcomes in a prospective cohort of new onset Chinese Parkinson's disease patients
J Neurol Neurosurg Psychiatry
Movement disorders society scientific issues committee report: SIC task force appraisal of clinical diagnostic criteria for Parkinsonian disorders
Mov Disord
Cognitive impairment in Parkinson's disease
J Neurol Neurosurg Psychiatry
Cited by (68)
Prediagnostic expressions in health records predict mortality in Parkinson's disease: A proof-of-concept study
2022, Parkinsonism and Related DisordersSex and gender differences in movement disorders: Parkinson's disease, essential tremor, dystonia and chorea
2022, International Review of NeurobiologyCitation Excerpt :A systematic analysis of the global burden of neurological diseases (GBD 2016 Neurology Collaborators, 2019) spanning from 1990 to 2016 has reported a M:F age-standardized prevalence ratio of 1:40, consistent with previous studies (Abbas, Xu, & Tan, 2017; Hirsch, Jette, Frolkis, Steeves, & Pringsheim, 2016; Moisan et al., 2016; Pringsheim, Jette, Frolkis, & Steeves, 2014). Higher M:F incidence ratios are reported in Western and South America, ranging from 1.3 to 2.0 (de Lau, Verbaan, Marinus, & van Hilten, 2014; Hirsch et al., 2016; Moisan et al., 2016; Taylor, Cook, & Counsell, 2007), in comparison to Asian populations (0.95–1.20) (Abbas et al., 2017; Maeda et al., 2017; Xu, Gong, Man, & Fan, 2014). Both M:F incidence and prevalence ratios for PD increase with age but in men, the increased incidence of PD does not parallel with a similar increase of prevalence.
Association of Pisa Syndrome With Mortality in Patients With Parkinson's Disease
2019, Journal of the American Medical Directors AssociationCitation Excerpt :However, it cannot be excluded that other factors, such as the low prevalence of history of smoking, might account for the higher prevalence in our population. Axial symptoms have been associated with increased mortality in PD patients.24–26 It has been hypothesized that such symptoms might reflect more extensive Lewy body pathology with involvement of multiple neurochemical systems.24
An increased rate of longitudinal cognitive decline is observed in Parkinson's disease patients with low CSF Aß42 and an APOE ε4 allele
2019, Neurobiology of DiseaseCitation Excerpt :Those demonstrating mild cognitive impairments are then at higher risk of developing dementia (Broeders et al., 2013; Janvin et al., 2006). Therefore, recognizing patients at the time of diagnosis who are at higher risk of early cognitive decline could also identify those at risk of earlier dementia, which is important to anticipate given its association with a greater loss of employment, caregiver stress and fatigue, increased cost to health systems, patient institutionalization, and decreased survival (Olanow and Schapira, 2013; Svenningsson et al., 2012; Marder, 2010; Armstrong et al., 2014; Burn et al., 2014; Barone et al., 2009; Martinez-Martin et al., 2011; de Lau et al., 2014; Kowal et al., 2013). Further, differentiating those patients at high risk for dementia as early as possible has therapeutic implications, since treatment is likely to be most effective prior to the onset of demonstrable cognitive decline.
Assessment of Cognitive-Driven Performance-Based Activities of Daily Living Dysfunction in Parkinson's Disease
2020, Journal of the International Neuropsychological Society